400mg SPN-812

DRUG4 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

ADHDAttention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

CompletedNCT02633527

Supernus Pharmaceuticals, Inc.Attention-Deficit/Hyperactivity Disorder (ADHD)

Start: 2016-02-01End: 2016-07-25Updated: 2021-10-27

Phase 3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

CompletedNCT03247556

Supernus Pharmaceuticals, Inc.ADHD

Start: 2017-11-20End: 2019-02-14Updated: 2021-07-02

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

CompletedNCT03247517

Supernus Pharmaceuticals, Inc.ADHD

Start: 2017-11-02End: 2018-10-17Updated: 2021-06-18

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

CompletedNCT03247543

Supernus Pharmaceuticals, Inc.ADHD

Start: 2017-10-31End: 2018-10-17Updated: 2021-07-08

Related Papers

Evaluation of the Efficacy of Viloxazine ER in Children and Adolescents with ADHD Inattentive and Combined Presentations

CNS Spectrums2024-10-01

Viloxazine Extended-Release Capsules in Children and Adolescents with ADHD: Final Results of a Long-Term, Phase 3, Open-Label Extension Study

CNS Spectrums2024-10-01

Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.

2023-04-052 citations

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

Pediatric Drugs2021-09-1516 citations

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

International Journal of Clinical Practice2021-05-1010 citations

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.

2021-03-0634 citations

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology2021-02-1818 citations